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What’s already known about this topic? (70 word max) Clinical studies have demonstrated 
tavaborole’s efficacy and safety in the treatment of onychomycosis. Using cadaveric nails, tavaborole has 
been shown to penetrate up to 4 layers of nail polish without disrupting the appearance and integrity of 
the polish.   
What does this study add? (70 word max) The current study investigates the efficacy of tavaborole in 
the presence of nail polish using an ex vivo healthy human distal nail model. Although previous studies 
have suggested that tavaborole may be compatible with nail polish, this is the first study to demonstrate 
fungicidal effects of tavaborole when applied to human nails with up to 4 layers of nail polish.  
What is the translational message? (70 word max) Many patients suffering from onychomycosis have 
a strong desire to mask their infection with nail polish. Until now, there was no evidence to suggest that 
any topical treatment for onychomycosis is efficacious in the presence of nail polish. The current study 
provides evidence that tavaborole penetrates polished nails and subsequently kills T rubrum in an ex vivo 
model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Background: Topical antifungal treatments for onychomycosis are applied to clean, unpolished nails for 
48 weeks or longer. Patients often wish to mask their infection with nail polish yet there is no evidence to 
suggest antifungal efficacy in the presence of nail polish. 
Objective: To determine if tavaborole retains the ability to penetrate the nail plate and inhibit fungal 
growth in the presence of nail polish. 
Method: Tavaborole was applied to human fingernails painted with 2 or 4 coats of nail polish, and 
unpainted nails in an ex vivo model. Nails were mounted on TurChub® chambers seeded with 
Trichophyton rubrum and allowed to incubate for 7 days. Antifungal activity was assessed by measuring 
zones of inhibition. 
Results: Tavaborole exhibited antifungal activity in all experimental groups. The zones of inhibition of T. 
rubrum for all experimental groups (2 or 4 coats of polish, unpolished) were significantly greater than 
infected controls (polished and unpolished), ps < 0.001. 
Conclusion: Tavaborole penetrates polished nails and kills T. rubrum in this ex vivo model.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
In 2014, the FDA approved two new topical antifungals for the treatment of onychomycosis, tavaborole 
and efinaconazole.1,2 For patients where oral antifungal medications are not an option or are undesired, 
the new topical antifungals present an alternative that circumvents concerns with oral antifungals (i.e., 
drug-drug interactions, hepatotoxicity). In particular, patients requiring multiple medications (e.g., 
elderly), or with diabetes and/or autoimmune diseases are likely unable to use oral antifungal medications 
and will benefit from the availability of topical antifungals.3  
 
There are two primary objectives when treating onychomycosis. The first is the eradication of the fungal 
infection or mycological cure. The second is clearance of the infection to produce a normal appearing nail 
or clinical cure. This objective is likely the primary concern for patients.4 Unsightly nails showing 
discoloration or structural deformity can be a source of distress and distraction for patients and lead to 
avoidance of social situations where nails will be seen. Nail polish is one solution for these patients; 
however, while nail polish may be applied while taking oral antifungals, product inserts do not provide 
guidance on their use in combination with nail polish.1,2 A topical treatment that could be used in the 
presence of nail polish would be advantageous and desirable to many patients. 
 
Tavaborole topical solution, 5% was shown to be effective in treating onychomycosis in two Phase 3 
studies conducted over 52 weeks on 1191 patients who did not use nail polish.5 Ex vivo work has also 
demonstrated that tavaborole 10% can penetrate the nail plate, having been detected in significantly 
greater concentrations as compared to ciclopirox 8% following daily application to cadaveric human 
fingernails for 5, 10 and 15 days.6 Tavaborole 10% applied to ex vivo fingernails penetrated the nail to 
inhibit the fungal growth of Trichophyton rubrum in a TurChub® chamber model. Conversely, no 
inhibition of fungal growth was observed for ciclopirox 8% and amorolfine 5%.6  
 
These ex vivo penetration studies were extended with investigation into the ability of tavaborole to 
penetrate the nail plate in the presence of nail polish. Tavaborole 5% was applied once daily for 14 days 
to human cadaveric nails painted with 1 to 4 layers of nail polish. Nail polish penetration was greater in 
painted nails than in unpainted nails, and overall accumulation of tavaborole increased over time.7 Nail 
polish appearance on cadaveric nails was evaluated over 7 days of consecutive application with 
tavaborole 5%, with tavaborole-treated polished nails showing no loss of nail polish integrity including 
lack of discoloration.8 It is yet to be determined if tavaborole can inhibit fungal growth in the presence of 
nail polish. The aim of the current study was to determine if a clinically relevant dose of tavaborole 5% 
applied over nail polish maintains fungicidal activity. To date, this is the first study of its kind to assess 
the ability of a topical antifungal to penetrate a nail and inhibit subungal growth of fungus in the presence 
of nail polish. 
Methods 
 
Following informed consent, fingernail clippings from healthy human volunteers were obtained. Inclusion 
criteria for nails were clean, disease-free, and unpainted in the last 6 months. Nails were frozen until 
ready to use. Upon thawing, nails were washed and cut into 3 mm x 3 mm sections before undergoing one 
of the following treatments with commercially available products (OPI): 
• Full salon: OPI base coat (2 L), 2 coats of OPI nail lacquer (2 L each, “An affair in red 
square”), OPI top coal (2 L) 
• Partially polished: 2 coats of OPI nail lacquer (2 L each, “An affair in red square”) 
• Unpainted 
TurChub® cell chambers (MedPharm Ltd) were calibrated and the compartment partially filled with 
potato dextrose agar (PDA). Chambers were seeded with 50 L T. rubrum suspension. Prepared nails 
were mounted to the chambers and a single application of 2 L of tavaborole, 5%, was applied to the nail 
surface and allowed to dry for 10 minutes. TurChub® chambers were then covered and incubated  
 
The experimental groups and controls are summarized in Table 1. The groups of interest were unpolished 
nails, full salon, and partially polished nails with tavaborole applied on top. Additionally, tavaborole was 
applied to nails prior to a full salon treatment. Infected and non-infected controls with polished and 
unpolished nails were included. The variable of interest was the growth of T. rubrum in the TurChub® 
chambers. The zone of inhibition was recorded for each chamber, measured centrally in a straight line 
from the underside of the nail (i.e., where the nail and agar are in contact) to the point of first signs of 
microbial growth. 
 
Data was analyzed using Statistical Package for Social Sciences (SPSS) version 19.0 (IBM, New York, 
USA). To determine if significant differences in the zone of inhibition were present between experimental 
groups, a one-way analysis of variance (ANOVA) with Tukey’s post-hoc test was used. Significance was 
set to  = 0.05. 
 
Results 
 
The maximum zone of inhibition (ZOI) that is possible in the chambers is > 3.2 cm and represents 
complete inhibition of T. rubrum growth. The zones of inhibition for the experimental and control groups 
are depicted in Figure 1 and representative TurChub® chambers in Figure 2. Of the experimental groups, 
tavaborole applied to unpolished nails produced the largest ZOI at 3.17 ± 0.12 cm, followed by tavaborole 
applied prior to full salon polish, 2.90 ± 0.1 cm. Tavaborole applied on top of partial polish and on top of 
full salon polish produced zones of inhibition of 2.67 ± 0.08 cm and 2.15 ± 0.24 cm, respectively. 
 
There were significant differences in the zones of inhibition among the experimental groups. The ZOI 
from tavaborole applied to unpolished nails (p < 0.001) and tavaborole applied prior to full salon polish (p 
< 0.05) were significantly greater than the ZOI seen with tavaborole applied on top of full salon polish. 
Tavaborole applied on top of partial polish did not produce a ZOI significantly different from the other 3 
experimental groups: unpolished, prior to full salon polish, or full salon polish (ps > 0.05). ZOI for all 4 
experimental groups were significantly greater than infected controls (polished and unpolished), ps < 
0.001. The ZOI of the tavaborole applied to unpolished nails and the tavaborole applied prior to full salon 
polish groups were not significantly different from non-infected controls (ps > 0.05). 
 
Discussion 
 
The present study investigated the ability of tavaborole, 5%, solution to penetrate ex vivo human 
fingernails and inhibit dermatophyte growth when applied in the presence of nail polish. A single, 
clinically relevant dose of tavaborole was able to penetrate both a salon polish (4 coats) and a partial 
polish (2 coats) in order to inhibit growth of T. rubrum, inhibition that was significantly greater than that 
of untreated controls. This is the first study to demonstrate the fungicidal ability of a topical antifungal in 
the presence of nail polish. 
 
Previous ex vivo work has used various methods to demonstrate that topical antifungals penetrate nails in 
the presence of nail polish. Penetration of tavaborole was quantified by measuring tavaborole in the 
receiving medium found in the chamber below the cadaveric nail.7 Radioactively-labeled efinaconazole 
was measured in solubilized nails.9 In short, tavaborole penetrated through cadaveric nails whereas 
efinaconazole penetrated into the nail plate. This suggests that both can penetrate and fight infection 
within the nail plate but that additionally, tavaborole may reach the site of deep seated infection in the nail 
bed. 
 
Vlahovic et al. reported that tavaborole penetrated nails with 1-4 coats of polish in greater amounts than 
the penetration observed for unpolished controls over 14 days.7 This differs from the current study where 
a larger ZOI, and presumably greater penetration, was observed with unpolished nails. Only one dose of 
tavaborole was used in the present work, while penetration was previously measured following 14 days of 
consecutive application of tavaborole; therefore, it is difficult to make parallels between these two studies. 
The Vlahovic et al. study suggests that repeated use of tavaborole over nail polish will result in continued 
penetration. Additional research is needed to understand why additional layers of nail polish may 
contribute to increased penetration of tavaborole. Theoretically, nail polish may serve as a form of 
occlusion, increasing nail plate hydration and improving drug penetration.10 Alternatively, the nail polish 
may serve as a reservoir that allows tavaborole to accumulate and remain in contact with the nail for an 
extended period of time.  
 
In terms of translating this data into clinical practice, the data suggests that patients who want to wear nail 
polish while using tavaborole 5% to treat their onychomycosis have good evidence to support this 
practice. Tavaborole appears to successfully penetrate the nail, reaching the site of the infection, and 
maintain its antifungal activity. Though this study compared typical combinations of nail polish, 
extrapolating the efficacy of a single dose as compared to consecutive daily doses is difficult. In addition, 
new topical treatments (tavaborole 5% and efinaconazole 10%) are applied transungually (on the dorsal 
nail surface) and subungually at the hyponychium. Accessing the site of infection by multiple routes 
likely contributes to the increased efficacy seen with newer topical antifungals.11 Likewise, subungual 
application may bypass the need to interfere with nail polish. Further, patients need not always wear nail 
polish, but could be more receptive to topical treatment if the option is available to wear nail polish in 
social situations. Importantly, it has been shown that tavaborole applied over nail polish does not alter the 
appearance of the polish8 and this should also encourage use. 
 
The current studies and previous investigations of penetration of tavaborole with and without nail polish 
have been performed on healthy nails. Recent research suggests that penetration of caffeine, a small 
hydrophilic molecule (194 Da), through onychomycotic nails is increased as compared to healthy nails. 
Interestingly, the presence of onychomycosis did not influence penetration of terbinafine (328 Da) or 
amorolfine (354 Da), both significantly larger molecules with differing physicochemical properties.10 
Considering that tavaborole is also a small molecule (152 Da) and slightly water soluble, there may be an 
increase in penetration of tavaborole in onychomycotic nails as compared to healthy nails. This should be 
kept in mind when interpreting this and other studies with healthy nails as it is a potential limitation.  
 
Males are disproportionately affected with onychomycosis, yet females are generally more likely to seek 
out treatment for onychomycosis. Particularly during warmer months, and regardless of sex, footwear that 
exposes the feet is common and expected. To avoid seeming out of place, nail polish provides a way to 
cover-up any unsightly nails to allow for wearing such footwear. The current study is the first to 
demonstrate the efficacy of a topical antifungal for onychomycosis in inhibiting fungal growth when 
applied over nail polish. Tavaborole remained efficacious in the presence of up to 4 layers of nail polish. 
How this ex vivo work with healthy nails will translate to clinical efficacy in diseased nails remains to be 
seen. However, this work presents an opportunity for topical antifungals to reach a population concerned 
with nail appearance but traditionally resistant to adhering to the long treatment durations of currently 
available topical treatments. 
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Table 1. Summary of experimental and control groups 
 
 Experimental Group Tavaborole dosing Replicates (n) 
A T. - Unpolished Nails 2 L applied to nail surface 6 
B T. - Salon Polished Nails 2 L applied to nail surface after 
polishing 
6 
C T. - Partial Polished Nails 6 
D T. - Salon Polished Nails 2 L applied to nail surface prior 
to polishing 
3 
E N/A - Unpolished Nails*  
N/A 
6 
F N/A - Polished Nails* 6 
G N/A - Unpolished Nails** 3 
H N/A - Polished Nails** 3 
T. = Tavaborole; N/A = not applicable 
* Infected controls were seeded with T. rubrum, but not treated with nail polish or tavaborole 
** Non-infected controls were not seeded with T. rubrum, and not treated with polish or tavaborole 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Zone of inhibition assay mean distance (± SEM) of T. rubrum on PDA in chambers mounted 
with full thickness human nails. Polished and unpolished nail surfaces were treated with tavaborole, 5%, 
(2 L) and incubated at 20-25°C for 7 days (n=6 per group, with the exception of groups D, G, and H 
where n=3 per group). The yellow bar represents the maximum range of length of agar (3.2-4.0 cm) 
within the TurChub® chambers. See text for statistical analysis. 
 
 
 
 
 
 
 
Figure 2. Representative TurChub® chambers showing the zone of inhibition (ZOI) following tavaborole, 
5%, applied to nail surfaces and incubated at 20-25°C for 7 days. 
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